XBP1 and type 2 diabetes mellitus: Another study using streptozotocin (STZ)-induced T2DM rat models has shown that circANKRD36 is highly expressed in T2DM rats, and silencing circANKRD36 can reduce blood glucose and inhibit insulin resistance and inflammation by targeting the miR-145/XBP1 axis [105].